Health Care·Biotechnology·$5.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.63 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.63 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach, emphasizing the importance of their clinical trials. They did not provide any updates on future guidance.
Management did not provide specific guidance for future quarters.
The company is focusing on its ongoing clinical trials and product development.
Xenon Pharmaceutical's earnings report showed a loss per share of $0.63, which contributed to a 4.5% decline in stock price. The lack of revenue information and forward guidance may have raised concerns among investors. The management's focus on clinical trials suggests they are prioritizing long-term growth over immediate financial performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
OCCIDENTAL PETE CORP
Nov 5, 2018